Revenue Showdown: Vertex Pharmaceuticals Incorporated vs Ionis Pharmaceuticals, Inc.

Vertex vs. Ionis: A Decade of Revenue Growth in Biotech

__timestampIonis Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014214161000580415000
Thursday, January 1, 20152837030001032336000
Friday, January 1, 20163466200001702177000
Sunday, January 1, 20175076660002488652000
Monday, January 1, 20185996740003047597000
Tuesday, January 1, 201911230000004162821000
Wednesday, January 1, 20207290000006205683000
Friday, January 1, 20218100000007574400000
Saturday, January 1, 20225870000008930700000
Sunday, January 1, 20237876470009869200000
Monday, January 1, 202470513800011020100000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: Vertex vs. Ionis

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and Ionis Pharmaceuticals, Inc. have been pivotal players. Over the past decade, Vertex has consistently outperformed Ionis, with its revenue growing from approximately $580 million in 2014 to nearly $9.9 billion in 2023. This represents a staggering 1,600% increase, showcasing Vertex's dominance in the market.

Conversely, Ionis has experienced a more modest growth trajectory, with revenues increasing from $214 million in 2014 to $788 million in 2023, marking a 268% rise. Despite this, Ionis has shown resilience, particularly in 2019, when it achieved its highest revenue of $1.1 billion.

The data highlights Vertex's strategic advancements and market penetration, while Ionis continues to innovate and expand its niche. As the biotech industry evolves, these companies remain at the forefront, driving innovation and growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025